Cargando…

A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter

Background: Direct oral factor Xa (FXa) inhibitors interfere with lupus anticoagulant (LA) assays challenging antiphospholipid syndrome diagnosis in treated patients. We evaluated a new device, called DOAC Filter, and its usefulness in this setting. It is a single-use filtration cartridge in which F...

Descripción completa

Detalles Bibliográficos
Autores principales: Farkh, Carine, Ellouze, Syrine, Gounelle, Louis, Sad Houari, Mama, Duchemin, Jérôme, Proulle, Valérie, Fontenay, Michaela, Delavenne, Xavier, Jourdi, Georges
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200390/
https://www.ncbi.nlm.nih.gov/pubmed/34136510
http://dx.doi.org/10.3389/fmed.2021.683357
_version_ 1783707591289864192
author Farkh, Carine
Ellouze, Syrine
Gounelle, Louis
Sad Houari, Mama
Duchemin, Jérôme
Proulle, Valérie
Fontenay, Michaela
Delavenne, Xavier
Jourdi, Georges
author_facet Farkh, Carine
Ellouze, Syrine
Gounelle, Louis
Sad Houari, Mama
Duchemin, Jérôme
Proulle, Valérie
Fontenay, Michaela
Delavenne, Xavier
Jourdi, Georges
author_sort Farkh, Carine
collection PubMed
description Background: Direct oral factor Xa (FXa) inhibitors interfere with lupus anticoagulant (LA) assays challenging antiphospholipid syndrome diagnosis in treated patients. We evaluated a new device, called DOAC Filter, and its usefulness in this setting. It is a single-use filtration cartridge in which FXa inhibitor compounds are trapped by non-covalent binding while plasma is filtered through a solid phase. Patient samples were analyzed before and after filtration: 38 rivaroxaban, 41 apixaban, and 68 none. Anticoagulant plasma concentrations were measured using specific anti-Xa assays and HPLC-MS/MS. LA testing was performed using dilute Russell Viper Venom Time (dRVVT) and Silica Clotting Time (SCT). Baseline median [min–max] concentrations were 64.8 [17.6; 311.4] for rivaroxaban and 92.1 ng/mL [37.1; 390.7] for apixaban (HPLC-MS/MS). They were significantly correlated with anti-Xa assay results (r = 0.98 and r = 0.94, respectively). dRVVT was positive in 92% rivaroxaban and 72% apixaban and SCT in 28 and 41% of samples, respectively. Post-filtration, median % of neutralization was 100% with rivaroxaban and apixaban concentrations of, respectively, <2 [<2–2.4] and <2 ng/mL [<2–9.6] using HPLC-MS/MS. No significant effect of DOAC Filter was observed on LA testing in controls (n = 31) and LA-positive (n = 37) non-anticoagulated samples. dRVVT and SCT remained positive in, respectively, 16 and 8% of rivaroxaban and 41 and 18% of apixaban samples. DOAC Filter would be an easy-to-use device allowing FXa inhibitor removal from plasma samples, limiting their interference with LA testing in treated patients.
format Online
Article
Text
id pubmed-8200390
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82003902021-06-15 A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter Farkh, Carine Ellouze, Syrine Gounelle, Louis Sad Houari, Mama Duchemin, Jérôme Proulle, Valérie Fontenay, Michaela Delavenne, Xavier Jourdi, Georges Front Med (Lausanne) Medicine Background: Direct oral factor Xa (FXa) inhibitors interfere with lupus anticoagulant (LA) assays challenging antiphospholipid syndrome diagnosis in treated patients. We evaluated a new device, called DOAC Filter, and its usefulness in this setting. It is a single-use filtration cartridge in which FXa inhibitor compounds are trapped by non-covalent binding while plasma is filtered through a solid phase. Patient samples were analyzed before and after filtration: 38 rivaroxaban, 41 apixaban, and 68 none. Anticoagulant plasma concentrations were measured using specific anti-Xa assays and HPLC-MS/MS. LA testing was performed using dilute Russell Viper Venom Time (dRVVT) and Silica Clotting Time (SCT). Baseline median [min–max] concentrations were 64.8 [17.6; 311.4] for rivaroxaban and 92.1 ng/mL [37.1; 390.7] for apixaban (HPLC-MS/MS). They were significantly correlated with anti-Xa assay results (r = 0.98 and r = 0.94, respectively). dRVVT was positive in 92% rivaroxaban and 72% apixaban and SCT in 28 and 41% of samples, respectively. Post-filtration, median % of neutralization was 100% with rivaroxaban and apixaban concentrations of, respectively, <2 [<2–2.4] and <2 ng/mL [<2–9.6] using HPLC-MS/MS. No significant effect of DOAC Filter was observed on LA testing in controls (n = 31) and LA-positive (n = 37) non-anticoagulated samples. dRVVT and SCT remained positive in, respectively, 16 and 8% of rivaroxaban and 41 and 18% of apixaban samples. DOAC Filter would be an easy-to-use device allowing FXa inhibitor removal from plasma samples, limiting their interference with LA testing in treated patients. Frontiers Media S.A. 2021-05-31 /pmc/articles/PMC8200390/ /pubmed/34136510 http://dx.doi.org/10.3389/fmed.2021.683357 Text en Copyright © 2021 Farkh, Ellouze, Gounelle, Sad Houari, Duchemin, Proulle, Fontenay, Delavenne and Jourdi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Farkh, Carine
Ellouze, Syrine
Gounelle, Louis
Sad Houari, Mama
Duchemin, Jérôme
Proulle, Valérie
Fontenay, Michaela
Delavenne, Xavier
Jourdi, Georges
A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter
title A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter
title_full A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter
title_fullStr A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter
title_full_unstemmed A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter
title_short A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter
title_sort diagnostic solution for lupus anticoagulant testing in patients taking direct oral fxa inhibitors using doac filter
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200390/
https://www.ncbi.nlm.nih.gov/pubmed/34136510
http://dx.doi.org/10.3389/fmed.2021.683357
work_keys_str_mv AT farkhcarine adiagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter
AT ellouzesyrine adiagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter
AT gounellelouis adiagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter
AT sadhouarimama adiagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter
AT ducheminjerome adiagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter
AT proullevalerie adiagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter
AT fontenaymichaela adiagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter
AT delavennexavier adiagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter
AT jourdigeorges adiagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter
AT farkhcarine diagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter
AT ellouzesyrine diagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter
AT gounellelouis diagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter
AT sadhouarimama diagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter
AT ducheminjerome diagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter
AT proullevalerie diagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter
AT fontenaymichaela diagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter
AT delavennexavier diagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter
AT jourdigeorges diagnosticsolutionforlupusanticoagulanttestinginpatientstakingdirectoralfxainhibitorsusingdoacfilter